Corient Private Wealth LLC Has $65.31 Million Position in Aflac Incorporated (NYSE:AFL)

Corient Private Wealth LLC lessened its position in Aflac Incorporated (NYSE:AFL - Free Report) by 1.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 631,367 shares of the financial services provider's stock after selling 7,485 shares during the quarter. Corient Private Wealth LLC owned approximately 0.11% of Aflac worth $65,309,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of AFL. Pettinga Financial Advisors LLC acquired a new position in shares of Aflac during the 3rd quarter worth approximately $203,000. OneDigital Investment Advisors LLC increased its position in shares of Aflac by 3.8% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 21,224 shares of the financial services provider's stock worth $2,373,000 after purchasing an additional 771 shares during the last quarter. CIBC Asset Management Inc increased its position in shares of Aflac by 4.6% during the 3rd quarter. CIBC Asset Management Inc now owns 90,103 shares of the financial services provider's stock worth $10,074,000 after purchasing an additional 3,969 shares during the last quarter. Empowered Funds LLC increased its position in shares of Aflac by 15.5% during the 3rd quarter. Empowered Funds LLC now owns 34,585 shares of the financial services provider's stock worth $3,867,000 after purchasing an additional 4,654 shares during the last quarter. Finally, Natixis Advisors LLC increased its position in shares of Aflac by 7.3% during the 3rd quarter. Natixis Advisors LLC now owns 300,630 shares of the financial services provider's stock worth $33,610,000 after purchasing an additional 20,402 shares during the last quarter. Institutional investors and hedge funds own 67.44% of the company's stock.

Remove Ads

Insider Transactions at Aflac

In other news, Director Charles D. Lake II sold 29,802 shares of the business's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $107.29, for a total transaction of $3,197,456.58. Following the completion of the transaction, the director now owns 49,962 shares of the company's stock, valued at approximately $5,360,422.98. The trade was a 37.36 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Joseph L. Moskowitz sold 1,000 shares of the business's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $107.63, for a total value of $107,630.00. Following the transaction, the director now directly owns 25,393 shares of the company's stock, valued at $2,733,048.59. This trade represents a 3.79 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 55,546 shares of company stock valued at $5,863,616. Corporate insiders own 0.80% of the company's stock.

Aflac Price Performance

Shares of NYSE:AFL traded up $0.20 during trading on Thursday, reaching $108.66. 1,754,630 shares of the company traded hands, compared to its average volume of 1,984,445. The company's 50 day moving average is $105.70 and its two-hundred day moving average is $107.65. The firm has a market capitalization of $59.39 billion, a PE ratio of 11.32, a PEG ratio of 3.24 and a beta of 0.93. The company has a quick ratio of 0.08, a current ratio of 0.10 and a debt-to-equity ratio of 0.29. Aflac Incorporated has a 52 week low of $79.31 and a 52 week high of $115.50.

Aflac (NYSE:AFL - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The financial services provider reported $1.56 EPS for the quarter, missing analysts' consensus estimates of $1.63 by ($0.07). Aflac had a return on equity of 16.20% and a net margin of 28.76%. As a group, sell-side analysts predict that Aflac Incorporated will post 6.88 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on AFL. Evercore ISI lowered their price target on Aflac from $104.00 to $102.00 and set an "underperform" rating on the stock in a research report on Wednesday, December 4th. Barclays reduced their target price on Aflac from $98.00 to $95.00 and set an "underweight" rating for the company in a research note on Friday, February 7th. Wells Fargo & Company reduced their target price on Aflac from $104.00 to $102.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 19th. JPMorgan Chase & Co. lifted their target price on Aflac from $90.00 to $94.00 and gave the stock a "neutral" rating in a research note on Tuesday, January 7th. Finally, Keefe, Bruyette & Woods reduced their target price on Aflac from $107.00 to $104.00 and set a "market perform" rating for the company in a research note on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat, Aflac currently has a consensus rating of "Hold" and a consensus target price of $103.36.

Aflac Profile

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.